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Th e elusive word
Th is is the second issue of 
Yale Medicine dedicated to a 
single theme. But as we edited, 
revised, and reworked the fea-
ture articles, it became clear 
to us that our initial theme, 
invention, was not quite right. 
Our feature on Rong Fan and his 
microchip does indeed chronicle 
the invention of a new medi-
cal and research tool. And our 
article on the Yale Center for 
Biomedical and Interventional 
Technology describes how sci-
entists from diff erent disciplines 
converge to craft new medical 
devices. But the story of how 
the iPad and the iPad mini are 
changing medical education is 
more about serendipity and a 
willingness to seize unexpected 
opportunities. We also tell about 
a patient willing to undergo a 
rare heart procedure in order to 
avoid having a heart transplant 
or a pump installed in his chest. 
Th e last two were not exactly 
about invention, but they are 
stories about people who sub-
scribe to the notion that chance 
favors the prepared mind; about 
people who are willing to try 
something new or diff erent. We 
needed a less trite way to say 
“thinking outside the box.”
We consulted dictionaries 
and a thesaurus. We looked 
online for articles and refer-
ences to creativity and ingenu-
ity. We talked with experts on 
the subject. Still, that one inci-
sive, inclusive word that would 
defi ne the magazine’s theme 
eluded us. Because we are a 
small shop, we all have other 
things to do. Th at allowed us 
to abandon the search for the 
missing word from time to time 
and dedicate ourselves to other 
tasks. And as we know from 
experience, as well as from the 
experts (see our introductory 
essay on page 10), inspiration 
often comes when it’s least 
expected; when ideas have had 
time to germinate in the back 
of one’s mind. We regrouped 
regularly to check in on the 
status of the magazine, and at 
one of those sessions, the word 
came to us. Not surprisingly, it 
had long been on a list gleaned 
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from the editor
I NGE N U I T Y A N D C R E AT I V I T Y, qualities essential to 
advancing scientifi c and medical knowledge, are the 
focus of this issue of Yale Medicine. We spoke with 
Dean Robert J. Alpern, M.D., about how institutions 
can promote such an atmosphere.
How does a medical school foster creativity? What are the conditions 
that make innovation likely? Th ere are a number of ways to enhance 
creativity. First and most importantly, you recruit the best people, 
who have a track record of creativity. Second, you provide an 
environment with opportunities for signifi cant interactions, and  
you make certain they receive outstanding mentorship early in 
their career. Th ird, you provide access to the best technologies. 
And then you let them loose and see what they accomplish.
When you recruit faculty, are you thinking about how they will interact? 
What do you think makes those interactions creative and productive? 
Th e goal is to recruit people who will have varied skills and knowl-
edge and can facilitate each other’s research. Th e best collabora-
tions are between people who share a common interest yet have 
very diverse training. I think that’s the key thing for a medical 
school, to bring together faculty with different backgrounds, 
different expertise, but enough of a common interest that they 
want to talk to each other.
It has been said that successful people actually fail more than others. 
Is failure an essential part of the scientifi c process?  Not necessarily. 
I think a courageous investigator should not be afraid to fail, and 
clearly the science that will be of the greatest impact runs the 
greatest risk of failure. But successful investigators often have a 
sixth sense that enables them to know what will likely succeed 
or fail, and to know when to abandon a failing approach.
Is framing the right question in research a matter of imagination? 
I think imagination is one part of it. Like any creative person, 
whether you’re an artist or do research, you need a knowledge of 
the tools, some imagination, and a sense of what is likely to be 
the best path to pursue. 
Th at last bit is both judgment and maybe a bit of intuition as well.
Yes it is both.  Th ere have been times in my research career when 
I had an idea and I just knew it was going to be positive, even 
though there was no basis for me to know that. In those cases, 
it most often turned out to be positive.
  “Successful investigators




















Gerard N. Burrow, M.D. ’58, 
HS ’66, died on December 14 at 
the age of 80. He served as dean 
of the medical school from 1992 
until 1997, when he became the 
David Paige Smith Professor of 
Medicine Emeritus and professor 
emeritus of obstetrics, gynecol-
ogy, and reproductive sciences. He 
had also published widely in the 
field of endocrinology. But Burrow 
is remembered as much for his 
warmth, humor, and remarkable 
range of outside interests as for his 
medical accomplishments.
“He was a brilliant academi-
cian,” Dean Robert J. Alpern, 
M.D., Ensign Professor of Medi-
cine, said in an interview, and 
“an honorable, gentle, nice per-
son who really cared about Yale.”
AT A M E MOR I A L S E RV IC E for the medical school’s 14th 
dean on January 17, friends, family, and colleagues  
honored a devoted academic physician who tweeted 
about iodine deficiency and cared for a whale with renal 
failure. They remembered a fun-loving man who cheered 
the animals at Mystic Aquarium’s sea lion shows;  
sported a fake earring at reunion; and relished sailing  
and tennis. And they recalled a kind mentor who was 
unfailingly supportive of colleagues.
  “An honorable person  
 who really cared about Yale”
»
Burrow’s son Peter put it 
another way, calling his father 
“a people’s dean.”
When Burrow accepted the 
deanship, recalled Michael 
Kashgarian, M.D. ’58, HS ’63, 
FW ’65, his best friend since 
medical school, he “brought a 
new atmosphere to the school.” 
Burrow worked to improve rela-
tions between the basic science 
and clinical departments, and 
to strengthen ties to Yale-New 
Haven Hospital, said Kashgarian, 
professor emeritus and senior 
research scientist in pathology.
A strong believer in the Yale 
system, Burrow wrote in 1999 
that modern medicine continues 
to require a “liberal arts physi-
cian.” Such a physician, the 
The late Gerard Burrow, 
the medical school’s 14th 
dean, is remembered for 




object of the Yale system, he 
wrote, is trained in science and 
the values of medicine, prepared 
for uncertainty, and able to adapt. 
He had previously expressed 
concern that medical schools 
in the 1990s were being forced 
to “carry out worldly business 
… such as industry-directed 
clinical trials and increasing 
amounts of purely clinical prac-
tice,” potentially blurring their 
academic focus. “He probably 
was the last of a group of medical 
school deans from an era when 
academic medicine was simpler, 
more idealistic, and less of a 
business,” Alpern noted.
Though not always at Yale, 
Burrow maintained connec-
tions to the school throughout 
his career. He helped to set up 
a high-risk obstetrics clinic 
at Yale-New Haven Hospital, 
raised money for a fitness cen-
ter in Harkness Dormitory, and 
led the board of trustees of 
the Cushing-Whitney Medical 
Library. He also wrote A History 
of Yale’s School of Medicine: 
Passing Torches to Others. One 
of Burrow’s metal sculptures, 
made when he took up welding 
as a hobby, resides at Yale-New 
Haven Hospital.
After completing his residency 
at Yale in 1966, Burrow joined 
the faculty and remained at Yale 
for the next 10 years, leaving for 
the University of Toronto in 1976. 
From 1988 to 1992, he served as 
dean of the UC San Diego School 
of Medicine, where he oversaw 
major infrastructure projects 
and recruited distinguished 
scientists—and sat on a stool over 
a pool of water for the annual 
Dunk-a-Dean event. (“History 
does not record,” said his son 
Peter, “how many times  
I stood in that line.”)
Burrow was an authority on 
iodine deficiency as well as on 
thyroid and other medical dis-
orders during pregnancy. Early 
in his career, he had studied the 
prenatal effects of the Nagasaki 
bombing with the United States 
Public Health Service in Japan. 
What he learned there sparked a 
lifelong interest in maternal and 
fetal health that led to dozens 
of publications over the ensu-
ing decades. He co-authored a 
book on thyroid disease with 
Kashgarian, and also wrote 
a popular reference work on 
medical disorders of pregnancy 
that ran to six editions.
After retiring from Yale, 
Burrow chaired the board of the 
UConn Health Center. He also 
became president and CEO of 
Sea Research Foundation, the 
parent organization of Mystic 
Aquarium. He helped establish a 
formal research program there, 
offering one veterinarian a plas-
tic beluga whale to which he’d 
attached a clay thyroid gland as 
a suggestion for a research topic. 
The aquarium’s Animal Parent 
program, which invites support-
ers to adopt a whale, penguin, or 
other aquarium animal, inspired 
Burrow to set up an Adopt-
a-Rare-Book program at the 
Medical Historical Library.
An aquarium colleague, Tracy 
Romano, Ph.D., recalled the day 
Burrow took her sailing shortly 
after she was hired. He handed 
the inexperienced Romano the 
helm, showing a faith in her 
ability that buoyed her. “He 
made everyone feel important 
and special,” Romano said. “His 
biggest contribution was the 
passion he had for life, and the 
compassion he had for people.”
—Jenny Blair
Throughout his career, 
Gerard Burrow main-
tained strong connec-
tions to the School of 
Medicine, even writing a 
history of the school.
»
Navigating the health  
care maze
After his service in the 82nd 
Airborne Division during the 
Vietnam War, Michael Joseph 
(not his real name) went into 
free fall. A one-two punch of 
PTSD and alcoholism left him 
chronically homeless and unable 
to take advantage of the health 
benefits available to veterans.
In 2012, when emergency 
room doctors sent Joseph to 








































Th roughout his tenure on 
the faculty of the School 
of Medicine, when he 
also served as deputy 
dean for education, 
Robert Giff ord, M.D., 
HS ’67, was known for 
the poems he wrote. 
At the memorial service 
in January, Giff ord 
remembered his friend 
and colleague Gerard N. 
Burrow, M.D. ’58, HS ’66, 
in verse:
I knew him as gentle 
and generously kind. 




His silence at times 
gave no clue.
REMEMBRANCE
Four years ago, physician 
Suzanne Lagarde had 
never heard of patient 
navigators. Now, she 
says, she has become a 
zealot and helped launch 
a course for patient 
navigators at Gateway 
Community College.
System in West Haven for psy-
chiatric treatment, he met 
Cheryl Eberg, a VA employee 
and fellow vet who found him 
shelter, scheduled his medi-
cal appointments, and got him 
bus passes. With Eberg’s help, 
Joseph, 58, is recovering. “She 
pretty much keeps up with 
all aspects of my daily living,” 
Joseph said. Without her assis-
tance, he said, “I’d be outside in 
the streets, drinking.”
Patients overwhelmed by ill-
ness, bureaucratic tangles, or 
insurance problems can benefi t 
from a professional companion 
like Eberg. She is a patient naviga-
tor whose job it is to be a human 
GPS as well as a motivator and 
cheerleader. As the name implies, 
patient navigators help patients 
fi nd their way through the 
maze of medical care—they help 
schedule appointments, arrange 
referrals for specialty care, and go 
to bat for patients with Medicare 
and Medicaid. Navigators are liai-
sons between patients and health 
insurers and providers, who, in 
addition to scheduling appoint-
ments, try to ensure that patients 
have the means to keep those 
appointments, fi nding them a 
ride when necessary. Th ey try to 
link homeless people, who often 
suffer from chronic health issues, 
with agencies that can help them.
Th anks to a program begun 
at Gateway Community College 
and inspired by Suzanne Lagarde, 
M.D., HS ’77, FW ’80, a Yale 
physician, Eberg is among the 
fi rst certifi ed patient naviga-
tors in Connecticut. She was 
one of 15 students who enrolled 
in Gateway’s initial Patient 
Navigator Training Program, 
which started in the fall of 2012 
with a grant from the state’s 
Department of Public Health. 
Since then, four more sections 
of the class have been offered at 
Gateway, one offering training 
for work with cancer patients, 
two offering general training, 
and one offering general train-
ing with additional training 
in colorectal cancer screening. 
Th is fall the program will offer 
training in preventive cancer 
screenings and diabetes.
“You’re riding the crest of 
a huge wave,” Lagarde, who 
became director of the Fair 
Haven Community Health 
Center last year, told the stu-
dents at the fi rst session of 
the inaugural class. Lagarde, 
assistant clinical professor of 
medicine (digestive diseases), 
recognized the importance of 
patient navigators when she 
helped start Project Access-New 
Haven, which helps the unin-
sured and underinsured fi nd pro 
bono specialty care. “Four years 
ago, I had never heard of the 
word. I’ve become a zealot.”
Patient navigation is the brain-
child of Harold P. Freeman, M.D., 
who started a program in New 
York City in 1990 to clear bar-
riers to detecting, treating, and 
comforting cancer patients. In 
2007, with the help of a $2.5 mil-
lion grant, the Harold P. Freeman 
Patient Navigation Institute was 
opened to establish standards 
and practices for the growing 
profession. Health care provid-
ers, Lagarde said, have come to 
understand that navigators are 
a cost-effective way to promote 
health. A navigator can help 
patients fi nd treatment before 
they show up in the ER. “Save 
two or three hospitalizations, and 
you could have a person’s salary 
for a year,” Lagarde said.
Members of a new profession help 
patients fi nd their way through the 














work with cancer patients, but 
find you want to work with the 
homeless,” she said. Interest in 
the class was “viral,” said Erika 
Lynch, Gateway’s continuing 
education coordinator for work-
force development.
The program consists of three 
eight-hour Saturday classroom 
sessions followed by 24 hours of 
shadowing patient navigators 
at work. What defines a patient 
navigator is “broad,” Lynch 
said. A navigator, said Lagarde, 
must be creative, caring, and 
persistent in dealing with prob-
lems that are critical but ancil-
lary to medical care, especially 
with homeless and mentally ill 
patients. “You’ve got to accept 
that there will be many closed 
doors,” she said. In addition to 
finding a way through those 
doors, a navigator must also 
act “like an Aunt Tilly,” and 
convince reluctant patients to 
fill out forms, manage finances, 
take medications, and show up 
for appointments. Since many 
navigators aren’t medical pro-
fessionals, they must also know 
their boundaries and not make 
such clinical decisions as helping 
patients interpret test results.
Navigators often “come 
from the same community as 
the patients they serve,” said 
Kevin Fiscella, M.D., M.P.H., a 
professor of family medicine at 
the University of Rochester and 
the author of studies showing 
the benefit of navigators. “This 
enables navigators to establish 
a rapport and even a trust—
somebody who speaks their 
Patient navigators can be 
especially helpful in dealing 
with patients who have problems 
above and beyond their medical 
conditions, such as the home-
less. “People who are homeless 
cost the system three to six times 
as much,” said David Rosenthal, 
M.D., the doctor in charge of a 
patient-aligned care team that 
serves homeless veterans at the 
VA. “They’re frequent users. To 
try to address that from a medi-
cal standpoint without a naviga-
tor is to work with a hand tied 
behind your back.”
Clinics also realize sav-
ings, because navigators help 
patients keep appointments so 
that devices like MRIs aren’t 
idle, said Christopher Borgstrom, 
program coordinator of Project 
Access. The tandem of patient 
and navigator “leads to amazing 
compliance,” he said. No-show 
rates for the program’s patients 
have fallen from 30 to 40 percent 
to just 2 to 4 percent.
When Lagarde approached 
Gateway officials, they thought 
the class fit well with the school’s 
mission—addressing the “chang-
ing academic, occupational, 
technological, and cultural 
needs of a diverse population,” 
according to the school’s web-
site. Discussions first centered 
on training people to help cancer 
patients through their grueling 
health care maze, but Victoria 
L. Bozzuto, Gateway’s dean of 
workforce development and con-
tinuing education, also wanted 
a class for generic navigators. 
“You may think you only want to 
language.” Eberg, for instance, 
served with the National Guard 
in Iraq in 2006 and 2007. “I don’t 
need to know anything else 
about her,” said another VA out-
patient who served in the Army 
in the Iraq and Afghanistan 
wars. In Iraq, Eberg was in 
charge of transportation sup-
port operations. Like the Radar 
O’Reilly character in the televi-
sion series M*A*S*H, she’s skilled 
at procuring things, like a cell-
phone for the veteran.
Navigators also provide a 
shoulder to cry on. When a 
48-year-old patient from the 
Dominican Republic had surgery 
for bladder cancer there, doc-
tors found another tumor and 
said her best hope was to get 
treatment in the United States. 
She spoke no English, didn’t 
qualify for Medicaid, and any 
appointments were months in 
the future. She wound up in the 
ER. “I had no guidance, no idea 
of what to do,” she said.
Edna Cruz-Cedeño and 
Giselle Carlotta-McDonald, 
patient navigators at Project 
Access, found physicians who 
treated her cancer, which is now 
under control.
“I had two cancers,” the 
patient said, “one in the body, 
and one of just thinking and 
worrying. That kills you faster.”
“As soon as she walked in  
the door, I could see it in her 
face,” Cruz-Cedeño said. “At  




Used wheelchairs and 
walkers fi nd new homes
A furry friend helps 
students, staff  unwind
A new skill for docs: 
writing for the public
Med students educate 
public on Obamacare
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 
on our homepage at 
yalemedicine.yale.edu.
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Gene mutation linked to 
Tourette syndrome
So much of what we do, we do 
on autopilot—whether tying our 
shoes or driving the same route 
to work. Functioning on autopilot 
frees our attention for other 
things, but it can also entrap us 
in infl exible and uncontrollable 
behaviors that assume lives 
of their own, said Christopher 
Pittenger, M.D., Ph.D., associate 
professor of psychiatry and in the 
Child Study Center and assistant 
professor of psychology, who 
studies how the brain’s cortical-
basal ganglia circuits help to auto-
mate routine behaviors.
In his clinical work and as 
director of the Yale OCD Research 
Clinic, Pittenger realized that 
many psychiatric disorders rang-
ing from obsessive-compulsive 
disorder (OCD) and Tourette 
syndrome to drug addiction 
entail habits turned into compul-
sions. Th ese disorders are also all 
associated with abnormalities in 
the basal ganglia, a brain region 
critical to motor control and 
procedural learning. To discover 
what is out of balance in a specifi c 
circuit, how it got that way, and 
how to fi x it, Pittenger studies 
affected patients; looks for genetic 
variations that may contribute to 
their condition; and observes the 
effect of those variations in mice 
to learn something new—with 
the ultimate aim of exploring the 
broader relevance of those fi nd-
ings in patients.
But discovering such genetic 
variants is tricky. Tourette 
syndrome, for example, is 
50 percent genetic, but it may 
involve perhaps hundreds of 
mutations that individually have 
a minuscule effect; thus, geneti-
cists often search for rare genes 
with large effects to gain new 
insights about a disorder.
In 2010, researchers at the 
School of Medicine found such 
a gene for Tourette, a syndrome 
characterized by involuntary 
repetitive movements and 
vocalizations called tics. A father 
and his eight children share 
this syndrome—and a mutation 
not found anywhere else in a 
gene called HDC. HDC normally 
codes for an enzyme that helps 
produce histamine, a signaling 
molecule associated with aller-
gies. Histamine also relays mes-
sages between neurons; it was 
the loss of this neurotransmitter 
function that seemed to cause 
Tourette in this family.
Pittenger’s team reported in 
the January 2014 issue of Neuron 
that the HDC defi ciency in 
mice disrupts the basal ganglia, 
which increases signaling by 
dopamine, a neurotransmitter 
associated with habit forma-
tion, Tourette, and other psy-
chiatric disorders. Mice with the 
mutation twitched their noses, 
sniffed, and groomed in a “rapid, 
repetitive and purposeless way, 
paralleling human behaviors.” 
But the tic-like behaviors disap-
peared when the mice received 
haloperidol, a drug that can 
lessen Tourette symptoms by 
blocking some effects of dopa-
mine. When researchers infused 
histamine into a mouse’s brain 
in another experiment, the 
infusion reversed the symptoms.
“Th at proved that the HDC 
mutation caused the disorder in 
these mice,” Pittenger said. “Th e 
mutation is so rare that it can-
not be the cause of Tourette in 
most people, but it’s a foot in the 
door for learning more about the 
disorder.” For example, HDC 
defi ciency in mice causes abnor-
malities in the levels of dopa-
mine receptors. When Pittenger 
went back to the family with 
the rare HDC mutation, PET 
brain imaging showed a similar 
irregularity in dopamine recep-
tors. Now he is asking whether 
this irregularity occurs in other 
Tourette patients and if so, what 
causes it.
“We’re optimistic that using 
this method again and again, 
we’ll fi nd previously unknown 
characteristics of Tourette that 
we can target with new treat-
ments. We’re not there yet, but 





When it comes to reproduction, men 
just don’t get the attention they 
deserve. How women’s health affects 
fertility has long been studied. Much 
less, however, is known about how 
men’s health affects reproduction, 
according to Rene Almeling, Ph.D., 
assistant professor of sociology, and 
co-author Miranda R. Waggoner, 
Ph.D., a postdoctoral research fel-
low at Princeton. Even though family 
history and health habits matter 
for men as well as women, the only 
place men are likely to get counsel-
ing on the topic is a sperm bank, 
say the researchers, whose findings 
appeared in December in the journal 
Gender & Society. This relative lack  
of attention to men leaves ques- 
tions unanswered, including how 
men’s reproductive contributions  
are understood.
MEN’S FERTILITY NEEDS MORE RESPECT
50 YEARS OF ANTI-SMOKING  
EFFORTS HAVE SAVED LIVES
Anti-smoking measures that began 
after U.S. Surgeon General Luther 
Terry warned of the dangers of smok-
ing 50 years ago have saved as many 
as 8 million lives, according to a Yale 
study published in January in JAMA: 
The Journal of the American Medical 
Association. According to first author 
Theodore R. Holford, Ph.D., the Susan 
Dwight Bliss Professor of Public 
Health (Biostatistics) and professor of 
statistics, along with researchers from 
the National Cancer Institute’s Cancer 
Intervention and Surveillance Modeling 
Network, the surgeon general’s 1964 
report was pivotal in changing atti-
tudes and behaviors related to smok-
ing. In addition to the now-familiar 
warnings placed on cigarette packages, 
taxes on tobacco have increased, 
advertising is restricted, and public 
smoking areas are limited.
WHO’S IN  
THE IN-CROWD?
Being in with the in-crowd is the 
result of a couple of simple and well-
established psychological principles 
that govern how we form allies and 
enemies, according to researchers 
at Yale and the University of North 
Carolina. We like people who are 
nice to us. And we like friends of our 
friends—and dislike our friends’ ene-
mies. The researchers used a computer 
model—with just 80 lines of code— 
to show that these two ingredients 
form the recipe for “us versus them,” 
and published their findings in the 
journal Psychological Science. David 
Rand, Ph.D., assistant professor of psy-
chology, economics and management, 
was a co-lead author of the study.
EASING PAIN WITH 
TARANTULA VENOM
A protein in the venom of the Peruvian  
green velvet tarantula blunts activ-
ity in pain-transmitting neurons, 
Yale scientists have found. The new 
screening method the scientists used 
to identify the protein has the poten-
tial to scour through large numbers 
of spider toxins in search of safe pain 
drugs and therapies. “The likelihood is 
that within the vast diversity of spider 
toxins we will find others that are 
active against other channels impor-
tant for pain,” said Michael Nitabach, 
Ph.D., J.D., associate professor of  
cellular and molecular physiology and 
of genetics, and senior author of the 













































a collection of recent  
scientific findings
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How creativity, knowledge, 
and vision advance medicine
W HEN W E IMAGINE ARCHIMEDES jumping out of his tub, shrieking “Eureka!” and running 
naked through the streets of Syracuse to celebrate his discovery, we miss the point. His eureka 
moment was not a sudden inspiration, but rather the culmination of hours, days, weeks, even 
months of letting a problem gestate in his mind. And it was no accident that the ancient Greek 
scholar’s epiphany came while he was soaking in a hot bath.
A key to creativity, according to R. Keith Sawyer, a psychologist at the University of North 
Carolina who studies creativity and innovation, is to follow up periods of intense study and 
research by letting your mind relax, wander, and imagine. Work hard, take time off, play, get your 
mind off the problem, and let it incubate. No wonder that Archimedes’ discovery—he saw the water 
level rise as he sank into the tub and realized he’d found a way to measure the volume of irregular 
objects—came when he was relaxing. John Lennon once described struggling for hours to write 
a song before giving up in frustration. He sacked out on a sofa and, in short order, the lyrics and 
melody to “Nowhere Man” came to him almost fully formed. (As the Beatle would sing in a different 
song, “Turn off your mind, relax, and fl oat downstream …”)
Creativity starts with asking the right question, being receptive to solutions all around us, being 
willing to combine different ideas, and freeing the mind to imagine. In this issue of Yale Medicine
we look at how clinicians, scientists, and educators at Yale have come up with creative solutions in 
surprising ways: Tiny machines that can decipher how cells talk to each other; an iPad app that has 
created a new dynamic in the classroom and in clinical clerkships; and a controversial procedure 
to treat aneurysms and spare patients a heart transplant. And the new Center for Biomedical and 
Interventional Technology creates a seemingly unlikely consortium of engineers, clinicians, and 
scientists to brainstorm new ways of developing medical devices.






















Biomedical engineer Rong Fan 
has developed a device that re-
veals a cell’s nature based on the 
proteins it secretes. “Cells use 
proteins to talk to each other,” 
he says. “I wanted to know what 
they were talking about.”
yalemedicine.yale.edu12
A biomedical engineer listens in on what 
proteins are saying.
A new device deciphers 
the language of cells
By Bruce Fellman Photographs by Robert Lisak
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Yale biomedical engineer Rong Fan’s entry into the 
innovation sweepstakes is not much to look at. Fan’s 
device, impressively named a single-cell, 45-plex 
protein secretion measurement platform, seems 
to be little more than a sandwich of two sheets of 
clear silicon rubber the thickness of window glass, 
each sheet a bit smaller than a credit card and bear-
ing a smaller, darker rectangle divided into 14 verti-
cal sections. It has no flashing lights, no intriguing 
noises, no moving parts, no signs of Applesque high 
design. Indeed, the object, displayed in Fan’s bustling 
laboratory on the first floor of the Daniel L. Malone 
Engineering Center, doesn’t appear to be doing any-
thing at all.
As inventions go,
A new device deciphers the language of cells
yalemedicine.yale.edu14
Smaller than a credit card, Fan’s 
“single-cell, 45-plex protein se-
cretion measurement platform” 
allows scientists to identify up to 
45 proteins secreted by cells. Th e 
simple, inexpensive, and portable 
machine provides more informa-
tion than other available detec-
tors, and does so with the most 
minuscule biological samples.
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Fan has formed a company, 
IsoPlexis, to commercialize his 
device. Kara Brower, a recent Yale 
College graduate who worked in 
Fan’s lab, is the company’s chief 
technology offi  cer. Collabora-
tors at Yale, other universities, 
pharmaceutical companies, 
and government labs are already 
using Fan’s invention.
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A new device deciphers the language of cells
Appearances deceive. Fan, a soft-spoken wizard of 
the nanorealm, has crafted an unprecedented way 
to trap individual cells as they travel highways only 
a billionth of a meter wide. In that same device, the 
engineer has incorporated a technology akin to super-
market barcodes that enables him to learn and listen 
to the language of cells. Collaborators at the School 
of Medicine and other universities, pharmaceutical 
companies, and government laboratories are starting 
to use Fan’s invention to uncover the hidden details of 
the cells’ stories. These investigations—all in their early 
stages—could help scientists make medical discoveries 
that lead to more effective vaccines, precision-targeted 
medications, a better understanding of autoimmune 
diseases, and even optimal strategies for diagnosing 
and treating such perplexing ailments as prostate can-
cer, glioblastoma, and myeloproliferative disorders.
“The potential applications are very broad,” said Fan, 
who has spun off a company called IsoPlexis to com-
mercialize the device. “We’re entering the era of cel-
lular medicine.”
how cells talk to each other
Human cells come in many shapes and sizes. In recent 
years, scientists have discovered that they can identify 
and characterize cells in both the immune system and 
in tumors by the suite of proteins they secrete. This 
proteomic signature, which may have dozens of indi-
vidual components, gives researchers and physicians 
alike important clues that they can use to, say, zero 
in on the cells that are instrumental in producing the 
right immune system response or those in a tumor that 
reveal its intentions, its vulnerabilities, its response to 
treatment, and its likely future direction. For example, 
in a patient diagnosed with a myeloproliferative neo-
plasm (MPN)—a chronic precancerous disorder of the 
bone marrow—the device could detect which cells in a 
population are secreting cytokine proteins that signal 
a high likelihood of MPN’s morphing into leukemia. In 
theory at least, this early warning could help research-
ers develop effective drugs that doctors could unleash at 
a time when a cure is most likely.
“Proteins are just like the words of a language,” said 
Fan. “Cells use proteins to talk to each other, and I 
wanted to know what they were talking about.”
Currently available tools like flow cytometers and 
mass cytometers do at least part of the listening job, but 
the devices are expensive and generally found only in 
major research centers like the School of Medicine. And 
because existing technologies can detect just a few of 
the many proteins secreted by cells, they give research-
ers sentences with many missing words. Filling in the 
blanks is vital to understanding cancer and other dis-
eases. “A tumor is like a community—it’s filled with all 
sorts of different cells talking to each other,” said Fan.
Getting a complete picture of tumor heterogeneity 
is important, Fan explained, because “what’s happen-
ing in the tumor microenvironment often determines 
the progression of the disease.” So Fan devised what 
is essentially a high-tech listening device—a way to 
isolate individual cells and record the stories they tell 
through the proteins they secrete—as many as 45 at a 
time. Not only can the simple, relatively inexpensive, 
and eminently portable platform provide more relevant 
information than any available detector, it can do so 
with the most minuscule of biological samples: a drop 
of blood or a tiny bit of tissue from a fine-needle biopsy.
“With the handheld device we’re refining, we may 
be on the verge of an important transition in medicine—
from qualitative to a much more quantitative analysis 
of a patient’s response to treatment,” said Kara Brower, 
a 2013 Yale engineering grad who worked in Fan’s lab 
and is presently chief technology officer of IsoPlexis.
from chemistry to nanotechnology
It’s too early to know whether Fan and his company 
have a game changer. But the fact that he’s in the 
game at all is something that few people, Fan included, 
would have predicted when he was growing up in 
China. “My interest in science was driven simply by 
curiosity,” he said, adding that when he came to the 
United States as a graduate student at the University of 
California, Berkeley, he had “very little interest in biol-
ogy or biomedical research.”
At Berkeley, Fan pursued a doctorate in chemistry and 
focused on better ways to make nanotubes and nano-
wires. But when he discovered that nature was already 
working on the scale of a billionth of a meter, Fan became 
hooked on biology. For his postdoctoral work, he opted 
for a more applied—and biomedical—career path at the 
California Institute of Technology and its NanoSystems 
Biology Cancer Center. There, Fan worked with James 
Heath, Ph.D., a nanochemist with a penchant for trans-
lational medicine and formidable inventive skills. On 
his lab’s website, Heath notes that “we focus on the 
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fundamental scientific bottlenecks that, if solved, can 
provide keys toward solving much larger problems.”
Fan would soon find some appropriate bottlenecks to 
tackle. One came from researchers looking for a better 
way to evaluate responses to vaccines by putting together 
a complete profile of the proteins secreted by single 
T cells. Another came from Fan’s search for devices that 
could uncover the proteomic fundamentals of cancer cells. 
In both cases, “the bottleneck was technology,” he said.
Fan realized that the solution lay in the nanotech-
niques he’d mastered at Berkeley. The proteins secreted 
by one cell in a normal-size test tube might be too low to 
detect easily—but put that same cell in a test tube about 
one-hundred-thousandth the diameter of a human hair, 
and the concentration of its tell-all secretions increases 
to the point of readability. “I’m pretty good at making 
things smaller and smaller,” Fan said.
At Caltech, Fan developed “one sexy-looking 
machine”—sexy, at least, to a nanoscale engineer adept 
at crafting minuscule chambers in clear plastic rect-
angles. The flow of cells was controlled by a pumping 
system that could handle fluid flow in tiny pipes. The 
individual cells were then isolated and allowed to 
interact with specific antibodies in a second micro-
chamber to generate what researchers call a barcode, 
which reveals the individual identities of a multitude of 
secreted proteins.
The device proved too complicated to use easily, 
so Fan, who joined Yale’s School of Engineering and 
Applied Sciences in 2010 as an assistant professor of 
biomedical engineering, built the proverbial better 
mousetrap. The new model has some 4,000 micro-
chambers, and by rethinking his initial design, Fan 
eliminated the need for pressure to move cells around. 
“Now everyone can use this device,” he explained.
nanobiotechnology reaches the clin ic
A number of Fan’s colleagues at the medical school 
are doing just that. Immunologist Joseph Craft, M.D., 
the Paul B. Beeson Professor of Medicine, professor of 
immunobiology, and section chief of rheumatology, is 
working with the engineer to profile the CD4 T cells that 
play a role in the development of such autoimmune dis-
eases as lupus. Richard Flavell, Ph.D., chair and Sterling 
Professor of Immunobiology, is using the device to 
A new device deciphers the language of cells
better categorize cells critical to regulating the immune 
response. Fan also has developed collaborations with 
researchers at the Memorial Sloan-Kettering Cancer 
Center and the National Institutes of Health.
But the partnership with perhaps the most immedi-
ate payoff is with Peter Schulam, M.D., Ph.D., profes-
sor and chair of urology, and a skilled surgeon who 
specializes in the treatment of prostate cancer. Fan and 
Schulam are developing a two-part strategy to bet-
ter deal with this disease—the most common cancer 
among men in the United States and the second lead-
ing cause of male deaths from cancer.
Prostate cancer poses one of the most difficult health 
care dilemmas for patients and physicians alike. “Not all, 
or even most, prostate tumors need to be treated,” said 
Schulam. “Some are what we call indolent: They won’t 
grow or spread over your entire lifetime, and they cause 
no functional problems. But because we can’t currently 
differentiate the indolent tumors from the aggressive 
ones—the ones that can kill you—we overtreat.”
Almost every man past 50 has had a digital rectal 
exam and the controversial blood test that looks for a 
marker called the prostate-specific antigen or PSA. If the 
results are suspicious, the patient is sent for a biopsy. If 
the pathologist assigns what’s called a Gleason score in 
the intermediate-to-high range to the cellular architec-
ture of the prostate sample, the patient is sent for treat-
ment—typically either surgery to remove the prostate or 
radiation to destroy the tumor. “But these are not benign 
procedures, and each has significant morbidities, such as 
impotence and incontinence, that can radically alter your 
quality of life,” said Schulam. “So it’s critically impor-
tant for us to learn how to distinguish patients who need 
treatment from those who do not.”
The urologist is refining an imaging system that will 
enable physicians to take targeted biopsies of the pros-
tate, and a subset of those cells will go to Fan’s lab to 
be placed on the device and characterized. The result-
ing proteomic profile will, the two researchers believe, 
enable physicians to more easily—and less subjectively—
read the minds of prostate tumors and single out only 
the bad actors for treatment. “We’re trying to increase 
our confidence level,” said Schulam. “What excites me 
most about Rong’s technology is that it gives us the 
opportunity to address a significant clinical problem 
and have a potentially great impact.” /yale medicine
Bruce Fellman is a freelance writer in North Stonington, Conn.
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In his lab, Fan has multiple 
manufacturing stations equipped 
with pressure tubes to make 
ultra-high-density antibody 
microarrays. When coupled with 
a single-cell microchip, a large 
panel of proteins in individual 
cells can be measured.
  Rong Fan // 
 “Cells use proteins to 
talk to each other, and 
  I wanted to know what 
 they were talking about. ’’
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 The history of innovation in scientific methodology dates to 
antiquity, with such advances as the astrolabe in ancient Greece and the seis-
mometer in China during the second century C.E. At Yale, it can be traced to the 
influence of such early figures as Benjamin Silliman, who created the first “mod-
ern” science laboratory at Yale in the early 1800s and was one of the founders 
of the medical school; and Russell Chittenden, who established the first labo-
ratory in the United States for the teaching of physiological chemistry. Both 
men helped guide the medical school toward a focus on experimental science, 
uncommon in an era when most physicians received only brief exposure to sci-
ence during their apprenticeships.
From this environment grew a thirst not only for new knowledge, but also 
for new tools with which to discover. Over the past 200 years, Yale scientists 
have devised numerous methods for expanding knowledge and accelerating the 
accumulation of data—and seeing or measuring things that had been previously 
beyond comprehension. The milestones that follow are excerpted from the 2010 
book Medicine at Yale: The First 200 Years, by Kerry L. Falvey, and from other 
sources including Yale Medicine and Medicine@Yale. Do you know of an example 





















































































The Nobel Committee rec-
ommends awarding the 
prize in physiology or medi-
cine to Yale scientist Ross 
G. Harrison, Ph.D., M.D., but 
because of World War I, no 
prize is given. Harrison is 
recognized for develop-
ing the technique of tissue 
culture, allowing cells to be 
grown outside the bodies 
of living organisms. His stu-
dent, Yale College alumnus 
John Enders, Ph.D., will win 
the Nobel decades later for 
his work growing the polio 
virus using this method—a 
development that was cru-
cial to the creation of the 
polio vaccine (as was work 
done in the 1940s and 1950s 
by Yale professor Dorothy M. 
Horstmann, M.D., FW ’43). 
1917
Arnold L. Gesell, Ph.D., M.D. ’15,  
establishes the forerunner of 
the Yale Child Study Center, 
and uses a new technique, 
longitudinal motion-picture 
studies, to follow child  




During his three years as 
a postdoc in New Haven, 
Herbert W. Boyer, Ph.D., 
FW ’66, produces two key 
papers on bacterial genet-
ics that set him on a course 
as a pioneer in the fi elds 
of genetic engineering and 
biotechnology. Boyer will 
later team up with Stanley 
Cohen, M.D., of Stanford to 
invent methods of genetic 
recombination for the large-
scale replication of human 
proteins in E. coli (above) 
and establish the world’s 
fi rst biotechnology company, 
Genentech, in 1976.
1963
John F. Fulton, D.Phil., M.D., 
constructs a decompres-
sion chamber in his lab 
during World War II to 
study the physiologic dan-
gers faced by Allied airmen 
fl ying in unpressurized 
planes at high altitudes. 
His work leads to better 
fl ight suits and education 
of pilots on the dangers 
of high-altitude aviation.
1940s
Seymour R. Lipsky, M.D., 
and Csaba Horváth, Ph.D., 
develop high-performance 
liquid chromatography, an 
essential tool for identifying 
or isolating substances for 
research and for determin-
ing the purity of biochemi-
cal molecules—a crucial 
step in drug development. 
Lipsky is at left with asso-
ciate Maurice Godet.
1964
John P. Peters, M.D., is the 
co-author of the text that 
will become the veritable 
bible of quantitative clinical 
chemistry, based on meth-
ods he devised to standard-
ize the analysis of blood 
and urine. As Donald Seldin, 
M.D. ’43, will later write, 
“Th e salutary result was a 
radical transformation of 
qualitative impressions 

























































































































































Alvan R. Feinstein, M.D., 
HS ’54, lays out the foun-
dation of the new science 
of clinical epidemiology in 
his book Clinical Judgment. 
Feinstein will propose new 
methods of study design, 
data interpretation, and the 
measurement of study out-
comes that are the standard 
in clinical research today.
1967
Gerhard Giebisch, M.D.,  
joins the Yale faculty. He 
and colleagues will devise 
novel micropuncture and 
patch-clamp methods to 
study how the kidney  
handles potassium—work 
that is largely responsible  
for current understanding  
of the mechanisms under-




George Palade, Ph.D., comes 
to Yale from The Rockefeller 
University, where he cre-
ated methods that com-
bined electron microscopy 
with new biochemical 
strategies to elucidate the 
fine structure and function 
of cellular organelles—an 
unparalleled body of work 
that laid the foundation of 
modern cell biology and 








































































Richard P. Lifton, M.D., 
Ph.D., then a fellow at the 
University of Utah, and col-
leagues apply the technique 
of linkage analysis to hunt 
for genes in the extended 
families of individuals with 
rare diseases. This new 
approach yields one of the 
first papers showing that 
a mutation intrinsic to the 
kidney is critical for blood 
pressure homeostasis. 
Lifton will come to Yale 
in 1993 and identify more 
than 20 genes associated 
with blood pressure, cardio-
vascular disease, and bone 
density using this method.
Robert G. Shulman, Ph.D., 
and colleagues at Yale tur-
bocharge their outdated 
MRI system by adding echo 
planar imaging, enabling 
one of the earliest func-
tional MRI studies; it will be 
the first to show the brain 
responding to individual 
events, in this case a single 
visual stimulus. Shulman’s 
team subsequently collabo-
rates with Greg McCarthy, 
Ph.D., to perform the first 
fMRI measurements of a 
person performing a cogni-
tive task.
1980
Jon W. Gordon, Ph.D. ’78, 
M.D. ’80, and Frank H. 
Ruddle, Ph.D., create the 
first genetically engineered 
mouse stably integrating 
foreign DNA. The so-called 
transgenic mouse has 
become an essential tool of 
biomedical scientists, allow-
ing researchers to add and 
delete genes in experimental 
animals in order to observe 
normal gene function and 
determine how genetic 










Building a better mousetrap (and mouse)
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Immunobiologists at Yale 
create a mouse with human 
versions of genes that 
are important for innate 
immune cell development 
and function: monocytes, 
macrophages, and natural 
killer cells. Th is “human-
ized mouse model” may be 
used to mimic the human 
immune system in scenarios 
of health and pathology, and 
may lead to new therapies 
for human disease.
Yale scientists develop a 
method of whole-exome 
sequencing that enables 
the detection of gene vari-
ants with a high degree of 
sensitivity. Th e approach is 
also highly effi  cient in that 
it examines only complete 
coding regions, or 1 percent 
of the human genome. Th e 
method is used to diag-
nose a kidney disorder in a 
5-month-old boy in Turkey, 
the fi rst-ever genetic diag-
nosis by whole-exome (or 
whole-genome) screening.
A group led by Laura 
Niklason, M.D., Ph.D., devel-
ops a method for creating 
artifi cial lung tissue, which 
succeeds in facilitating gas 
exchange for a brief period 
in a rat model. Th e advance 
is cited by Time maga-






Tian Xu, Ph.D. ’90, and col-
leagues engineer the piggy-
Bac transposon in mice. Th is 
“jumping gene” makes the 
mouse a mutant factory: 
when the animal breeds, 
the transposon causes 
random genetic mutations 
in the mouse’s off spring—
one gene per mouse is 
disabled. Compared to 
current methods for making 
experimental mice, known 
as knockouts, using piggy-
Bac is 100 times quicker 
and cheaper. PiggyBac also 
carries a genetic marker 
to turn the mouse pink for 
easy identifi cation.
2001
Vincent A. Pieribone, Ph.D., 
and colleagues identify 
two corals (Lobophyllia 
hemprichii and Favites 
spp.) that produce fl uores-
cent proteins, which, like 
jellyfi sh green fl uorescent 
protein, are used as mark-
ers of gene expression. In 
2013, they will develop a 
new molecular probe called 
ArcLight, which allows one 
to measure electrical activ-
ity of genetically targeted 
sets of neurons in a living 
organism, a prerequisite for 
understanding the complex 
language of the brain.
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 Yale debuts an incubator  
for medical inventions
T H I N K OF A MOR E FOR M A L V E R S ION  of a Silicon Valley garage 
that’s also a think tank and fundraiser, and you have an idea 
of what the new Yale Center for Biomedical and Interventional 
Technology (CBIT) will do. CBIT is a consortium of engineers, 
clinicians, and other researchers whose goal is to foster the 
development of medical devices.
CBIT, said Peter G. Schulam, M.D., 
Ph.D., chair and professor of urol-
ogy, is to be “the point of entry 
for an idea.” He initiated a similar 
program at UCLA and said that 
Yale’s center will be a clearing-
house for devices ranging from 
prosthetic limbs to nanoparticles.
“This center will allow us to 
have a standard place to go rather 
than have the faculty hunt around 
and say, ‘I need a guy with a pump. 
I need a guy with a circuit board,’ ” 
said John Geibel, D.Sc., M.D., vice 
chair and professor of surgery 
(gastrointestinal), and professor of 
cellular and molecular physiology.
Yale has long recognized that 
inventions cannot live on ideas 
scattered all over the place,” he 
said. Dedicated lab space will allow 
engineers to test a physician’s idea 
to see whether it’s feasible.
W. Mark Saltzman, Ph.D., chair 
and Goizueta Foundation Professor 
of Biomedical Engineering, and 
professor of cellular and molecu-
lar physiology and of chemical 
engineering, said one key aspect is 
holding workshops with experts 
from various fields. “That’s hard 
to do in this field,” said Saltzman, 
who developed the plan with 
Schulam. People with skills capable 
of developing devices “might not 
be in the same department. They 
might not be in the same school.”
CBIT will have an executive 
board composed of experts from 
the medical, engineering, and 
management schools that will 
meet monthly to vet ideas. Once 
approved, an idea will undergo 
engineering development. “A lot 
of ideas get cast aside because you 
don’t think it’s possible,” Saltzman 
said. “But a clever engineer might 
say, ‘This might be possible.’ ” If 
the engineers can fashion a proto-
type, clinicians will put it through 
clinical or preclinical studies. If 
it passes these tests, School of 
Management experts will advise 
on fundraising and perhaps bring-
ing the device to market. But as 
Shrader cautioned, “If no one can 
figure out how to make money on 
it, it’s not going to be made.”
—John Dillon
alone, and has a veritable alphabet 
soup of centers to capitalize on 
them—the Center for Engineering 
Innovation and Design; the Yale 
Entrepreneurship Institute; the 
Office for Cooperative Research 
(OCR); and the Yale Center for 
Clinical Investigation. CBIT will 
partner with all of them, and has 
also approached the University 
of Connecticut, the National 
Institutes of Health, and commer-
cial entities like Eigen, the medical 
imaging firm in California, and 
Covidien, the medical technology 
company located in Connecticut.
The other centers each have 
areas of expertise, but not the capa-
bility to bring a device to fruition, 
said Thomas Shrader, Ph.D., OCR’s 
director of strategic corporate alli-
ances. Most importantly, none 
have the space. Great universities 




















  Pramod Bonde // 
 “Th is can be a permanent fi x 
for those patients who have been 
  so sick and have lost all hope. ’’
yalemedicine.yale.edu28
Cardiovascular surgeon Pramod Bonde takes an 
unconventional approach to repairing aneurysms, 
sparing some patients transplants or implants.
Old problem, new tools
By Colleen Shaddox Photographs by Harold Shapiro
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 in intensive care cracking jokes, 
and he’s still at it as he sits in the kitchen of his 
Wallingford home in February. “I need one more  
hospital stay to get down to 160,” he said—a jibe  
at his struggle to lose weight. Between the jokes a 
story emerged about his massive heart attack last 
year and the surgery and rehabilitation that followed. 
He finally grew serious when he talked about his 
children—Frankie, 13, and Marissa Rose, 9—whose  
pictures decorate the refrigerator, the walls, and every 
shelf of the family’s home. When doctors told him 
he’d need a heart transplant, his thoughts flew to 
them. “Am I going to see them graduate high school?”
Lucian Capozzo 
spent a lot of  
his time 
Old problem, new tools
Lucian Capozzo avoided a heart 
transplant thanks to a procedure 
rarely used in the United States.
yalemedicine.yale.edu30
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visitors to the lab’s website. “This has been the corner-
stone of our approach to solving complex problems in 
cardiac surgery.”
If his work creating new devices suggests that Bonde 
is interested primarily in technological solutions, that’s 
only half of the story. The SVR procedure requires a fair 
bit of artfulness on the surgeon’s part. Despite extensive 
imaging, surgeons cannot really see the damage to the 
heart until they are looking inside the patient’s chest. 
Knowing where damaged muscle ends and healthy mus-
cle begins is a matter of experience and judgment. “That 
really is the challenge of the procedure,” explained Bonde.
Adapting the procedure to individual patients is criti-
cal to its success. Bonde has seen men and women of vari-
ous ages benefit from it even though their heart attacks 
left different kinds of damage. Among his patients was 
a woman with heart failure whose medical team was 
discussing withdrawing life support. After an SVR and a 
bypass operation in November 2013, the woman was able 
to enjoy the winter holidays with her family—and go out 
shopping for presents.
Although SVR is now more broadly used to address 
scarring that contributes to heart failure, the proce-
dure was originally conceived as a strategy to repair 
ventricular aneurysms like Capozzo’s. His aneurysm— 
a thinning of the heart wall that makes it vulnerable 
to rupture—had forced his left ventricle from its natu-
ral elongated shape into a life-threatening spherical 
form. To fix it, Bonde would have to cut away damaged 
muscle and use a mesh patch to reshape the ventricle. 
Bonde usually performs this operation in conjunction 
with CABG, a bypass operation.
This procedure spares patients the many lifestyle 
adjustments that an LVAD dictates, like bathing restric-
tions and the need to cart the device and a backup power 
source everywhere. SVR can also postpone—or make 
unnecessary—a heart transplant or implantation of an 
LVAD. Capozzo never had to wait for a donor, worry about 
immune system rejection, or take immunosuppressive 
drugs. “This can be a permanent fix for those patients 
who have been so sick and have lost all hope,” said Bonde.
indigestion or heart at tack?
Capozzo had not paid much attention to the symptoms 
that first surfaced during a dinner he had hosted for his 
Old problem, new tools
Today Capozzo, 48, is back at work, and in his spare time 
shoots baskets with the kids. He’s planning family trips 
to Disney World and the Jersey shore and looking forward 
to more distant milestones, like sending his children off 
to proms and dancing at their weddings.
Capozzo was in heart failure in early 2013 when he 
was referred to Pramod Bonde, M.D., assistant professor 
of surgery, for a left ventricular assist device (LVAD) as 
a bridge to transplantation. The device keeps the heart 
pumping until a donor heart becomes available—if the 
patient is fortunate. More than 10,000 Americans have 
died since 1995 while waiting for a donor heart.
Instead of an LVAD, Bonde proposed to repair 
Capozzo’s heart through surgical ventricular restoration 
(SVR), an operation first performed by Vincent Dor, M.D., 
in France in the 1980s. Though Bonde regularly performs 
LVAD procedures and heart transplants, he said that it is 
important to match the procedure to the patient’s partic-
ular need—even if that means doing a relatively uncom-
mon operation.
Bonde is one of only a handful of surgeons in New 
England who perform SVR, and he might seem an 
unlikely proponent of the surgery. It relies more on 
surgical skill than technological support, yet much of 
Bonde’s work focuses on technology. He is director of 
mechanical circulatory support in the Department of 
Surgery at Yale and a frequent collaborator with engi-
neers. His research group has close to a dozen medical, 
engineering, and undergraduate students and research 
assistants working on problems that must be overcome 
before an innovative artificial heart can be made viable 
for humans. Bonde’s team is also working on designs 
for an artificial lung, a portable device for producing 
circulation and oxygenation support outside the hospi-
tal, and a mechanical CPR device. They are developing 
a wireless LVAD instrumentation for minimally inva-
sive cardiac surgery, as well as simulators for teaching 
surgical techniques. One of the most advanced projects 
is for a tiny, implantable pump that would switch on 
only when needed, as a pacemaker does, allowing 
some patients to be weaned from the device. But Bonde 
is also a surgeon who, with new techniques and tools at 
his disposal, likes to think outside the box.
“We believe a creative and imaginative environ-
ment is essential to innovation,” says a message to 
yalemedicine.yale.edu32
One of Pramod Bonde’s recent 
inventions is a replacement  
for the left ventricular assist  
device, which he holds in his 
hands and must be implanted 
in the patient’s chest. Medical 
student Brian Letzen, who  
works in Bonde’s lab, holds the 
smaller device.
33Spring 2014
wife’s family in November 2012. “I blamed it on the extra 
sausage and peppers.” Capozzo found it impossible to sleep 
lying down that night. “I felt like I ate fast and the food got 
stuck somewhere,” he said. Because he never felt pressure 
on his chest, it didn’t occur to him that he’d had what his 
doctors later concluded was a massive heart attack.
He spent the following weeks treating with antacids 
what he still wrote off as indigestion. After a night shift 
at his job as an IT professional, he sat down to a snack of 
tuna and potato chips. Again, he had the feeling that he 
just couldn’t lie down, and again he blamed it on what he 
had eaten—he may have had his second heart attack.
His sister Louise saw her brother looking sicker by 
the day. In mid-December she took him to the Yale-New 
Haven Shoreline Medical Center in Guilford, where an 
electrocardiogram revealed that his left ventricle was 
barely pumping. “I’ve never seen so many doctors run 
toward a patient in my life,” said Capozzo.
“How did you get here?” a physician asked.
His sister had driven him, he answered. How had 
Capozzo gotten from the car to the emergency room? the 
doctor asked.
“I walked in,” he said.
“You walked in!”
Discussing the case in his office months later, Bonde 
pulled up an MRI of Capozzo’s heart before surgery. The 
heart was misshapen and filling most of the chest cavity. 
Capozzo had arrived at the Shoreline Medical Center with 
an ejection fraction—a measurement of the amount of 
blood the heart pumps with each ventricular contraction—
of 8 percent. The normal rate is between 50 and 60 percent.
The immediate plan was for a heart transplant, until 
Capozzo was referred to Bonde. “I was pretty upbeat 
about the transplant,” Capozzo remembers. But he was 
relieved to hear of another option and immediately 
agreed to SVR. He had the surgery in April 2013.
The procedure should be far more common than it 
is, according to John Conte, M.D., a professor of surgery 
and director of mechanical circuitry support at Johns 
Hopkins, where Bonde learned the procedure. “There are 
many, many reasons why you don’t want to do an LVAD 
or transplant. They are expensive therapies. They are 
therapies that are fraught with complications; and they 
are therapies that, despite their best intentions, have lim-
ited lifespans,” Conte said.
But SVR had gotten bad press from a trial initiated 
in 2002 that reported that the procedure, often done in 
conjunction with coronary bypass, conferred no advan-
tage over bypass alone. Conte and Bonde say that the 
Surgical Treatment for Ischemic Heart Failure (STICH) 
trial was flawed. Conte points out that low enrollment 
prompted the National Institutes of Health to extend the 
search for volunteers to countries that did not deter-
mine whether patients were good candidates for SVR 
and did not perform the operation according to study 
guidelines. Editorials in medical journals criticized the 
trial, and studies conducted before and after STICH 
showed a benefit over bypass alone. Yet the well-publi-
cized study made physicians hesitate to make referrals 
for SVR—a chilling effect that Conte says has moderated 
in recent years. SVR is more common in Europe, where 
surgeons have more experience with the procedure and 
have achieved good outcomes.
matching patient and treatment
Since his surgery, Capozzo has had a chance to reflect 
on the behaviors that contributed to his heart di- 
sease. “I did this to myself,” he said. “I smoked, ate 
bad, never exercised.”
That’s changing. Now he hits the elliptical trainer 
three or four times a week. He misses his high-salt diet, 
especially his favorite guilty pleasure, pickle juice. But for 
the most part, he’s passing up potato chips and heading 
for the big bowl of fruit he keeps on the kitchen island. 
He would like to reach out to other patients who are can-
didates for SVR and talk with them about his experience.
Not every patient referred for transplant is a good 
candidate for SVR, Bonde stressed. Those most suited for 
SVR, Bonde said, are patients who need a bypass or valve 
operation, have scar tissue from a previous heart attack, 
and have a resulting low ejection fraction. Conte agreed. 
“It is a great therapy for a small number of patients,” he 
said. “And it should be done by people who have exper-
tise in that therapy, like Dr. Bonde; people who also have 
at their disposal the opportunity to do heart transplants 
and LVAD. It allows you to match the right operation 
with the right patient.” /yale medicine
Colleen Shaddox is a freelance writer in Hamden, Conn.
Old problem, new tools
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By Jill Max
How a pocket-size tablet is 
changing medical education
 Students and faculty embrace the unexpected 
 benefi ts of iPads in the classroom and the clinic.
In the Winchester Chest Clinic, 
medical student Ruth Wang’ondu 
uses her iPad to check a patient’s 
chart and recent lab tests. “She 
fi nds things out in a quarter of 
the time it takes me,” says Robert 












Ruth Wang’ondu arrives at the Winchester Chest 
Clinic. The clinic is packed with patients making up 
appointments missed due to a rash of recent snow-
storms, and Wang’ondu, who’s in the M.D./Ph.D.  
program, is armed with the arsenal of references and 
notes that every medical student requires during  
clinical rotations. Last year, these materials would have  
filled her pockets, weighing down her petite frame 
and forcing her to rifle through a multitude of pages 
to check a dosage or learn more about a lab value. This 
year, all these materials, as well as additional texts, 
videos, and access to Epic, Yale’s electronic medical 
record system (EMR), are contained in her iPad mini, 
a 5x8-inch device that fits neatly in the pocket of her 
white coat or the back pocket of her scrubs.
On a rainy  
day in February,
How a pocket-size tablet is changing medical education
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In the fall of 2011, Yale made headlines by switching 
from paper copies of course materials to providing 
every medical student with an iPad. Two of the key 
incentives were to go green by saving paper and to 
ensure that students had a HIPAA-compliant mecha-
nism for protecting patient information. The change 
was transformative—students now have constant 
access to the entire medical curriculum, electronic 
textbooks, instructional videos, and Web content, 
as well as the opportunity to develop and download 
applications that render their educational experience 
highly interactive. In the clinical years, however, stu-
dents weren’t using their full-size iPads as much as 
expected, which led the School of Medicine last fall to 
offer iPad minis to third-year students at a subsidized 
rate. Out of 100 students, 99 accepted the offer. The 
mini provides unfettered access to updated course con-
tent, Internet resources, and patient records in a light, 
thin, and small device. The mini and its big brother 
enrich the medical school experience in ways that are 
both obvious and unexpected. They are changing the 
way students learn.
24 /7 access to medical records
Wang’ondu’s first patient at the chest clinic is a 4-year-
old girl with latent tuberculosis (TB). She has seen 
the girl before during her year-long elective at the 
TB and HIV clinics. Before she enters the exam room, 
Wang’ondu uses her tablet to compare today’s blood 
pressure reading with a previous one from November.
She uses the encrypted device in other settings as well.
During the HIV clinic, a supervisor often asks her to 
look up patients’ lab results—a task more easily accom-
plished with the mini than at the clinical work sta-
tion, which is in another room and in high demand. If 
Wang’ondu wants to prepare for the cases she’ll be see-
ing in the clinic, she can log in to Epic the night before. 
She uses a wide variety of apps to help her learn, 
including Lab Values Pro, which explains lab values; 
Heart Sounds to hear what cardiac conditions sound 
like; and a video atlas as an ultrasound reference and to 
view laparoscopic images. In the HIV clinic, for exam-
ple, she frequently uses Epocrates, a mobile and online 
clinical and drug reference resource, to show patients 
photos of pills when they’re not sure which ones 
they’ve discontinued or may be causing side effects.
inventing new apps
Students have embraced the iPads in their curricu-
lum so much that some are devising new applications 
for them. Last year, Paul Guillod, a second-year stu-
dent, created Quizzler to help study for boards. Amy 
Yuan, a first-year student, turned a neurobiology lab 
manual into a digital book that Michael Schwartz, Ph.D., 
Since the School of Medicine 
began issuing iPads to medical 
students in 2010, the devices 
have changed the dynamic in the 
classroom. The iPad allows stu-
dents to sync to the most recent 













associate professor of neurobiology and associate dean 
for curriculum, now distributes to all of his students. 
A self-proclaimed “closet geek” who spearheaded the 
iPad initiative, Schwartz praised the tablet’s versatility, 
interactive capability, and multimedia features. “It’s not 
the iPad per se; it’s the technology that the iPad allows 
in our pedagogy that’s important,” said Schwartz.
Unlike many medical schools, where students 
download one file at a time from their learning man-
agement system (LMS), Yale enables students to sync 
electronically to the latest version of curriculum mate-
rial. “Students tell us that if we expect them to use 
these materials and take notes on them, they have to 
be able to access what they’re actually seeing during 
the lecture. If a faculty member changes a slide the 
night before, the outdated version isn’t good enough,” 
said Schwartz. “When faculty come into the lecture 
hall with modified presentations that have not been 
uploaded to the LMS, within two or three minutes that 
lecture material is converted at the podium, uploaded 
to the server, and students are notified, so they have 
immediate access to the most up-to-date material.”
In some instances, the iPad is changing the medi-
cal school’s approach to teaching. Some instructors 
use Quizzler and other Web-based applications for 
interactive small-group discussions and quizzes. The 
instructor can control what students see on their iPads 
and ask them questions. The responses are delivered 
to the instructor as well as to other students. This 
process enables everyone to see the correct answer 
and encourages discussion. The app tracks the stu-
dents’ correct and incorrect answers on their iPads, so 
that group members know where to concentrate their 
efforts. “In many of our small-group settings, it has 
dramatically changed the interactive nature of the dis-
cussions,” said Schwartz.
The iPads, Schwartz has found, are also a terrific 
delivery mechanism for instructional videos that he 
encourages faculty to produce. In contrast to podcasts 
of full lectures, these short videos help students pre-
pare for class more efficiently. Schwartz has set up a 
studio in the library for making and annotating the 
videos. “It expands a little bit what we’re capable of 
delivering to students in terms of curricular materials,” 
he said.
the ipad in  the clin ic
Back in the clinic, Wang’ondu checks the 4-year-old’s 
record and confirms that she’s taking the prescribed 
medication. When she learns that the girl’s surgeon has 
postponed a tonsillectomy due to the TB diagnosis, she 
enters the surgeon’s name in her tablet, so that she can 
follow up later. After examining the girl, she excuses 
herself to present her findings to Robert Baltimore, M.D., 
professor of pediatrics (infectious disease) and of epide-
miology (microbial diseases). She answers his questions, 
sometimes consulting her tablet. “She finds things out 
in a quarter of the time it takes me,” said Baltimore.
Wang’ondu and Baltimore move on to their next 
patient, a 5-year-old girl. Before entering the exam 
room, Wang’ondu orders a chest X-ray for Baltimore 
to sign, then looks up the girl’s chart on her device. 
It shows that the girl had a positive PPD skin test for 
latent TB, but a blood test gave a contradictory result—
negative. Wang’ondu also discovers that the girl had 
received Bacillus Calmette-Guérin (BCG) immuniza-
tion, which is given in some countries to prevent TB. 
The BCG may explain the positive PPD.
After she and Baltimore finish with the 5-year-old, 
Wang’ondu returns to the clinical work stations. The 
room is normally crowded with attendings, fellows, 
residents, and nurses who need access to the comput-
ers. Before she had her mini, Wang’ondu would wait 
her turn, but now she can consult and update patient 
records before, during, and after patient visits. During 
a lull in activity, she sits down at a work station to 
write her notes in the charts of both patients, referring 
to notes she had taken on her mini.
She finishes typing in her notes on Epic and then 
heads back to her surgery rotation. She is out the door 
quickly; using her mini, she accesses the surgery sched-
ule and locates the case she is following. She didn’t have 
to decide before leaving home that morning which notes 
and texts she might need or want to review during the 
day. “You have all the information you could possibly 
need in that tiny electronic device,” she said. “I think it’s 
the best thing that’s ever happened.” /yale medicine
Jill Max is a freelance writer in Trumbull, Conn.
How a pocket-size tablet is changing medical education
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59
Number of students  
currently majoring in 
biomedical engineering.
19
Number of students 
majoring in biomedical 
engineering in 1999, the 
first year of the program.
58
Number of Yale-affiliated 
biotech startups.
99
Percentage of Yale third-
year med students who 
use an iPad on rounds.
1896
Year of the first X-ray 
image taken at Yale.
1958
Year of the invention of 
continuous electronic 
fetal monitoring at Yale.
36
Number of years between 
when Yale medical school 
graduate A.C. Gilbert first 
marketed the Erector Set 
and when an early heart 
pump was developed at 
Yale in 1949 using $24.80 
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 Winning fame  
and fortune at play
Alfred Carlton Gilbert, M.D. 
1909, won an Olympic gold 
medal for pole vaulting in 
1908; graduated from the 
School of Medicine a year 
later; founded a company in 
New Haven to produce magic 
tricks that same year; and in 
1913, introduced the product 
for which he is best known: 
the Erector Set.
Throughout his whimsical 
and wildly successful career, 
Gilbert had a Mary Poppins-
like way of combining work 
and play. As a youngster in 
Oregon, he got his friends to 
help him bring in firewood 
by saying that they couldn’t 
play in his barn, which he had 
rigged up as an athletic club, 
until the chore was done. “I 
have never worked at anything 
to make money unless it was 
fun, too,” he wrote in his auto-
biography, The Man Who Lives 
in Paradise. Success through 
play became his brand.
Gilbert knew the impor-
tance of persistence as well 
as prizes to successful entre-
preneurship. In addition to 
his athletic pursuits, Gilbert 
had trapped squirrels, caught 
wildcats, and sold magazine 
subscriptions in exchange for 
rewards, including the magic 
set that sparked his career. 
Athletic ambitions brought 
Gilbert to Yale for medical 
school; he hoped to become 
a college athletic director. 
But in addition to study-
ing, Gilbert started giving 
magic shows to finance his 
Yale education. Just before 
graduating, he co-founded 
the Mysto Manufacturing 
Company to produce and sell 
magic sets. Then, inspired 
by the towers built to hold 
up the wires on the newly 
electrified railroads, Gilbert 
created his famous construc-
tion toy—a set of miniature 
steel girders, wheels, a real 
working motor, and accom-
panying parts—in time for 
the 1913 holiday season. He 
also renamed the enterprise, 
still headquartered in New 
  How alumnus A.C. Gilbert made the Erector Set  
 his brand and inspired generations of young people,  
   including seven Nobel laureates.
  By Ashley P. Taylor
Haven, after himself: the A.C. 
Gilbert Company.
What distinguished the 
Erector Set from similar prod-
ucts, as Gilbert’s biographer 
Bruce Watson wrote, was 
that Gilbert made himself a 
brand. He affixed his photo, 
signature, and message to 
Erector ads and publications. 
Boys wrote him letters. His 
message? “Win Fame While at 
Play,” as one ad said. “He uses 
his story,” said Bill Brown, 
director of the Eli Whitney 
Museum and Workshop in 
Hamden, Conn., “to promise 
that if you play with [Erector 
Sets], you’ll grow up to 
become a tycoon like him.”
Gilbert also sold the 
idea that his products were 
educational—and they were, 
indeed, inspiring many sci-
entists and engineers. Last 
fall, the Eli Whitney Museum 
featured an exhibit about 
Gilbert and the Erector Set, 
including the Erector memo-
ries of seven Nobel prizewin-
ners. In a nearby notebook, 
museum visitors could 
record their reminiscences 
of Gilbert’s “toy.” “My first 
exposure to my friend’s 
Erector Set inspired me to 
become a mechanical engi-
neer,” one visitor wrote. 
More directly, Erector Set 
parts were used in notable 
inventions—including the 
first heart pump, powered 
by an Erector Set motor and 
invented by the late William 
H. Sewell Jr., M.D. ’50, then a 
Yale medical student; and his 
professor, the late William 
W.L. Glenn, M.D.
Despite his charismatic 
public face, Gilbert was 
somewhat retiring in person. 
“A.C. was clearly the man 
in charge, but quiet,” said 
grandson Jeff Marsted, who 
remembers “sledding, base-
ball, golf, apple picking, etc.,” 
at his grandparents’ home in 
North Haven. “We all knew 
it, not by his personality but 
what he represented.”
Gilbert left a legacy both 
scientific and physical. At 
the Eli Whitney Museum 
exhibit, visitors worked 
together on a model of 
Manhattan’s Woolworth 
Building, a landmark 
skyscraper completed in 
1913—the same year the 
first Erector Sets were mar-
keted. The exhibit model 
was 22 feet tall and required 
3,800 girders. The organizers 
had no trouble at all gather-
ing donated pieces for the 
exhibit, Brown said. “I don’t 




OPPOSITE PAGE  
Meccano, the main com- 
petition to A.C. Gilbert’s 
Erector Set, also pro-
duced sets for model 
airplanes. In 1929 Gilbert 
bought the company  
that produced Meccano 
in the United States.
CLOCKWISE FROM TOP LEFT 
An illustration from 1913 
shows the possibilities 
of an Erector Set, here a 
gantry and crane.
The Erector Set appeared 
on the market in 1913 at a 
toy fair in New York City. 
By 1935, Gilbert had sold 
more than 30 million sets.
Gilbert, who won a gold 
medal in the 1908 Olym-
pics for pole vaulting, 
came to the School of 
Medicine to study sports 
medicine.
In 1949 Yale medical 
student William Sewell 
and heart surgeon Wil-
liam Glenn developed a 
heart pump, powered by 
a motor from an Erector 
Set, and supplemented 
with laboratory supplies 
and dime store items.  




































































































Now an assistant professor of 
anthropology and psychiatry at 
New York University Langone 
Medical Center, she continues 
to study those intersections of 
social forces and medicine,  
with a goal of providing acces-
sible care to all. She studies 
community-based health move-
ments and the ethnic marketing 
of pharmaceuticals. She recently 
completed a one-hour docu-
mentary video that examines 
the historical and contempo-
rary political-economic forces 
shaping the treatment of opiate 
addiction in the United States.
Hansen traces her interest in 
social inequalities to 1992, when 
she graduated from Harvard 
and took a job as program offi-
cer at the National AIDS Fund’s 
 More than easing  
the suffering of patients
»
W H E N H E L E NA H A N S E N, M.D. ’05,  PH.D. ’05, decided to go to medical 
school, she wanted to learn more than just how to relieve the suffering of 
individual patients. Just as health care professionals use biotechnology to 
treat patients, they should also understand and act upon the institutional, 
social, and cultural influences on people’s health. “I wanted to combine 
medical training with community-based research,” Hansen said, adding 
that “it was important to understand how social forces influence health.”
New Jersey office. “It was the 
early ’90s, people were dying 
like flies, but it was an excit-
ing time in AIDS policy,” she 
said. “We were helping to design 
studies, inventing community 
collaborations.”
She went on to the M.D./Ph.D. 
program at Yale and completed 
her doctoral studies in anthro-
pology rather than the basic sci-
ences most students choose. That 
was the start of a wide-ranging 
career that, in her first year of 
the program, brought Hansen 
to Havana with a delegation of 
medical students who visited the 
clinical research facilities of the 
Instituto de Medicina Tropical 
Pedro Kouri. For her doctoral 
thesis, Hansen did fieldwork 
in Puerto Rico on Pentecostal 
ministries founded and run by 
people recovering from narcot-
ics addiction. The ministries 
operate a network of faith-based 
detox units and residential 
rehabilitation centers that com-
prise the majority of the drug 
treatment programs in Puerto 
Rico. They are modeled on simi-
lar ministries in the inner cities 
of the United States.
During her residency at the 
New York University Langone 
Medical Center/Bellevue Hospital, 
Hansen continued to study social 
causes of health disparities. Part 
of her work included a political-
economic and ethnographic study 
of buprenorphine, a synthetic 
opioid approved by the FDA in 
2002 to treat opioid addiction. 
Opioid maintenance treatment, 
she realized, fell into two tiers—
office-based buprenorphine ther-
apy largely available to affluent 
abusers of prescription opioids, 
and DEA-regulated methadone 
yalemedicine.yale.edu42
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Even as a medical stu-
dent, Helena Hansen  
was drawn to research 
that shows how social 





















clinics for low-income heroin 
injectors. Th e result, according 
to Hansen, was a further stigma-
tization of drug addiction, and a 
shift in emphasis away from psy-
chiatric services as a component 
of recovery to cursory 15-minute 
medication checks. With fund-
ing from NIDA, she is comparing 
primary care-based addiction 
treatment with psychiatry-based 
substance abuse programs to 
determine their impact on the 
stigma that patients experience, 
as well as how the programs 
affect patients’ social networks 
and access to resources.
Her interest in video began 
with the realization that journal 
articles do not draw a broad 
audience. She had been par-
ticipating in a video therapy 
group started by an art therapist 
Hansen has observed that 
interest in the social forces that 
shape health inequalities is 
growing among clinicians. With 
her colleague Jonathan Metzl, 
M.D., Ph.D., she organized a 
series of conferences and a spe-
cial issue of the journal Public 
Library of Science Medicine
on the topic of what she and 
Metzl term “structural compe-
tency.” Th e term indicates the 
need for physicians and other 
health practitioners to work at 
the level of institutions, policies, 
and community collaborations 
to reduce health inequalities. At 
their fi rst conference on struc-
tural competency in 2012, they 
expected to fi ll a room with 
capacity for 70 people—more 
than 200 showed up, a blend of 
medical school faculty and stu-
dents, state and city health pol-
icy makers and administrators, 
community health advocates, 
and social scientists. “We need 
to think and act collectively 
»
Hip names and 
modern life inspire 
a children’s book
Matthew Goldenberg’s book for 
children also pokes fun at their 
yuppie parents.
When Matthew Goldenberg, 
M.D. ’03, became an uncle, his 
niece, Ava, came into a world 
that was vastly different from 
the one depicted in Goldenberg’s 
own childhood storybooks. 
“Bobby has a new ball” no lon-
ger described this world.
“Th e vocabulary that a baby 
needs today was not going to 
be found in a traditional baby 
book,” Goldenberg said. 
Little Ava lived in Park Slope, 
Brooklyn, home to hip babies 
with cool names and urban gear. 
“Th ere are a lot of yuppie baby 
things in the world now. And 
many of my friends were nam-
ing their babies Ava, Sophie, 
Jack. Nobody my age is named 
Ava or Jack,” he said.
Modern babies needed a mod-
ern book, thought Goldenberg, 
a psychiatrist who joined the 
medical school faculty last fall. 
So he wrote A is for Artisanal: 
An Alphabet Book for the Hip, 
Modern Baby. Th e 26-page 
picture book, illustrated by 
physician-turned-cartoonist 
Benjamin Schwartz, M.D., is as 
entertaining for parents as it is 
for their children.
Th e fi rst page reads, “Ava 
adores artisanal asiago.” From Ava 
to Zoey, the book is a tongue-in-
cheek portrayal of modern urban 
life, complete with farmer’s mar-
kets, iPads, vegetarians, and yoga.
  An alumna’s journey through social 
movements and forces that affect health.
around health and health care,” 
Hansen said. “Clinicians need 
to collaborate with others who 
have expertise in education, 
housing, and city planning. 
Th ere are myriad ways to work 
across disciplines to create better 
health conditions.”
—Jennifer Kaylin
and two patients with produc-
tion and editing experience. 
Members narrated and pro-
duced fi ctional stories, commen-
taries, or documentaries about 
their lives. When she shows the 
videos, Hansen said, residents 
and premed students are better 
able to engage with the subject 
matter—the political and ethi-
cal quandaries of treating opiate 
addiction with opioid medica-
tions. In an academic setting, 
she learned, video "is a really 
good tool for communicating."
Why government, 
academia, and industry 
need to work together.
Art of Caring: med 
students chronicle the 
unsung heroes of YSM.
Photos and video 
of 98 smiling faces 
on Match Day.
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 
on our homepage at 
medicine.yale.edu
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enjoyed writing the page for the 
letter B, “Bjorn is brought to 
brunch in a Bob. Bob is brought 
to brunch in a Bjorn.”
“I had no idea what a Bob 
was until some friends who 
had recently had a baby men-
tioned it,” Goldenberg said of 
the three-wheeled all-terrain 
stroller that’s suitable for jog-
ging. (A Björn is what older gen-
erations would call a Snugli.)  
“It seemed like every conver-
sation I had with new parents 
after that involved Bobs. So that 
was my baby gift to my brother 
and sister-in-law.” 
It’s as if Goldenberg shares an 
inside joke with parents while 
their children enjoy pictures 
and alliteration in lines like 
“Noah needs nightly news from 
NPR” and “Jack jocularly jabs 
like Jon Stewart.” Reviewers on 
Amazon.com get a good-natured 
laugh out of Goldenberg’s jabs. 
“BrooklynSFDad” wrote in his 
online review, “A hilarious skew-
ering of urban parenting. Having 
brought my babies to brunch in 
both a Björn and a Bob, I can say 
with certainty that I am the target 
(and target demographic) of this 
hilarious book.”
Goldenberg agrees. “It’s a good 
way for us to chuckle at ourselves. 
It’s a comment on modern hip-
ster society. I eat Greek yogurt. 
I go to a farmer’s market every 
Saturday. I like women’s soccer,” 
Goldenberg said, referring to 
images that appear in the book. 
“It’s meant to poke lighthearted, 
good fun at my generation.”
He returned to New Haven in 
September after 10 years away. 
He had spent four of those years 
on the faculty of the Uniformed 
Services University of the Health 
Sciences in Washington, D.C., 
and a year in London pursu-
ing a master’s degree in global 
mental health. At the School of 
Medicine, he plans to develop 
programs in global mental 
health for students.
In his free time, he plans to 
write more books.
“I’ve always had a very diverse 
set of interests: history, politics, 
football, documentary films, 
geography. One of the fun things 
about writing is the opportunity 
to pursue some of that.”
—Sonya Collins
Goldenberg observed many 
parents and children as research 
for his book, but not being a 
parent himself allowed him the 
time to write the book and shop 
for publishers. “When I’d come 
home from work and Whole 
Foods and CrossFit,” he joked, 
poking fun at the hipster aspects 
of his own life, “I’d send it out to 
publishers and agents.” But he 
can’t say the book is completely 
separate from his day job.
“It allows me a creative side 
that I don’t always find in my day-
to-day work, but as a psychiatrist, 
I am an observer and appreciator 
of human behavior. That certainly 
informed this book.”
A is for Artisanal is his first 
professional artistic endeavor, 
but what Goldenberg calls his 
“creative impulse” manifested 
years ago.
“I was a producer of the  
second-year show. It was one 
of the highlights of my medi-
cal school career,” he said. “The 
writing of this book comes from 
that same creative impulse.”
Goldenberg is an attending 
psychiatrist in the psychiatric 
emergency room at Yale-New 
Haven Hospital. He is also the 
interim medical director of a 
new psychiatric observation unit 
that became fully operational in 
November. The unit is for patients 
whose psychiatric symptoms may 
not require hospital admission 
but do require a longer stay than a 
typical ER visit.
Prior to earning his medi-
cal degree, Goldenberg was a 
history major in Yale College. 
Matthew Goldenberg 
was inspired by his niece, 
Ava, and his nephew, 
Joseph, (in photo) to write 
a children's book that 
















 How Harlan Krumholz  
got big pharma to open its data
watch an interview with 




H A R L A N K RU M HOL Z , M.D.,  H A S S T R E E T C R E D. In scientific circles, 
the Harold H. Hines Jr. Professor of Medicine (Cardiology) and 
professor of investigative medicine and of public health (health policy), 
is known as a gadfly who calls out pharmaceutical giants for—among 
other things—sitting on clinical trial data that might hurt their bottom 
line. So when Krumholz came up with a plan to collaborate with big 
pharma to release such data to other scientists, his colleagues told him 
it would never happen. “People said that industry would never share 
data. If they did share data, they would never share them with me 
because they’d think I’d be too tough on them,” Krumholz recalled.
{To nominate a subject for Q&A, contactYale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
an agreement with Johnson 
& Johnson. Under the agree-
ment the company relinquishes 
control of its clinical trial data 
to YODA, which sends the data 
to two independent research 
groups for analysis. The com-
pany will initially release  
pharmaceutical trial data,  
followed by data from clinical 
trials of medical devices and 
consumer products.
“I have not done this alone,” 
Krumholz said. His collabora-
tors include Joseph Ross, M.D., 
M.H.S. ’06, assistant professor 
of medicine; Cary Gross, M.D., 
professor of medicine; and the 
British physician and academic 
Richard Lehman, M.D. Leading 
But it did happen. Twice.
First, Medtronic allowed 
Krumholz to farm out their 
clinical data to two independent 
research groups. They came back 
with slightly different analyses, 
reinforcing Krumholz's view 
that opening up data can only 
benefit science, physicians, and 
patients. And early this year 
the Yale University Open Data 
Access (YODA) Project, which 
Krumholz directs, entered into 
YODA’s steering committee is 
bioethicist Ezekiel Emanuel, 
M.D., Ph.D. “The progress we 
have made is a tribute to the 
companies that have been will-
ing to lead a new approach. We 
forged a vision of what could be 
accomplished together.”
Krumholz talked with Yale 
Medicine in February about 
the agreement with Johnson & 
Johnson and his career in out-
comes research.
How did you get involved  
in health policy and  
outcomes research?  
When I was a Yale undergrad, 
I had the opportunity to do 
an internship at the office of 
rural health service in North 
Carolina. They had set up a 
series of clinics run by nurse 
practitioners and connected 
to general practitioners at a 
distance. My job was to learn 
about those community 
clinics and do some surveys 
about what the challenges 
and obstacles were. Before 
that I had worked in basic 
science labs and thought that 
that might be a direction that 
I would take. This [intern-
ship] turned me more toward 
thinking about the public and 
society and patients, and how 
you could generate knowledge 
that would have a practical 
impact on people.
What is outcomes research?  
It’s saying we want to know 
at the end of the day whether 
we’ve helped people. Have 
patients experienced a good 
outcome? Are they in a better 
place than they would other-
wise be?
What was the problem you 
wanted to solve with YODA?  
It turned out in our research 
that half of clinical trials are 
not published within three 
years—and many of them are 
never published. If science 
is to be progressive and self-
correcting, it is critical that 
the data be available for mul-
tiple groups to look at—to 
draw their own conclusions, 
to put the results in public 
view, and to allow dialogue 
to take place.
Why are studies not being 
published? It is not entirely 
clear. We saw that stud-
ies that are sponsored and 
owned by industry are now 
published at a slightly higher 
rate than previously. We 
did an audit of NIH and saw 
again that half the studies at 
three years were not being 
published. This is part of our 
culture—people run to fin-
ish studies; then they move 
on to the next thing. They 
may lose interest. They may 
get results that didn’t excite 
them. Maybe there is a profit 
motive and the results aren’t 
what they were looking for.
How did YODA begin?  
We were trying to figure out 
how we could partner with 
industry and show a way 
forward. Prior to that, litigate 
and regulate were the two 
primary ways to get data to 
be more widely shared. There 
was a third path, which was 
to partner. It turned out 
Medtronic was having some 
problems with a product. I 
approached the chief science 
officer and started a huddle 
with their leadership. I said 
you’d probably hire a con-
sultant, hire someone to look 
at the data, do an internal 
review, circle the wagons, 
and try to defend yourselves. 
How about a different path? 
What we’re going to do is 
share all the data assets 
related to these products; 
we’re going to partner with 
an independent academic 
organization; and we’re going 
to allow them to enlist two 
expert groups to do reviews. 
Why did Johnson &  
Johnson agree to  
participate in YODA?  
At Johnson & Johnson there 
seemed to be sincere interest 
in this third path. They have 
a credo that is built on trust 
and serving the public. And 
they had had some issues 
with some of their products. 
They wanted to be leaders  
in setting the standard for 
the future.
How will YODA benefit 
patients? There should be a 
more complete picture of the 
balance of risks and benefits 
of the drugs and clinical 
strategies that lie in front of 
them. There should be more 
confidence in the scientific 
system—that it’s not just one 
group that’s maybe getting 
paid by another group that 
has a vested interest. It’s 
a more trustworthy, more 
credible system that is pro-
ducing information better, 
faster, and cheaper.



















 Why we spend 
more but get less
When New York Mayor 
Michael Bloomberg proposed 
to limit sales of jumbo sodas 
in 2012, dissent on the banks 
of the Hudson could be heard 
clear down on the Mississippi 
Delta. Th e Mississippi legisla-
ture responded in 2013 with 
the so-called anti-Bloomberg 
bill, which forbids towns and 
cities from making such rules 
governing food and drink as 
restrictions on soda size or 
requirements to list calorie 
counts on menus. Th at’s in 
a state where one in three 
residents is obese—a circum-
stance that costs Mississippi 
an estimated $4.2 billion extra 
in medical costs each year.
For Elizabeth H. Bradley, 
Ph.D. ’96, professor of public 
health and director of the 
Yale Global Health Initiative, 
Americans’ narrow view 
of health maintenance 
combined with a culture of 
individualism explains why 
initiatives like Bloomberg’s 
raise hackles. With co-
author Lauren A. Taylor, 
M.P.H. ’09, Bradley explores 
this hypothesis in a new 
book, Th e American Health 
Care Paradox: Why Spending 
More is Getting Us Less.
Th e paradox, of course, is 
that the United States spends 
far more on health care than 
do other developed countries; 
yet Americans have shorter 
life expectancies, lose more 
babies, suffer more often 
from diabetes and heart dis-
ease, are more likely to be 
obese, and so on.
Bradley and Taylor argue 
that one cause of the “spend 
more, get less” system is 
that Americans regard good 
health as synonymous with 
access to doctors. “Most of 
the evidence would say that 
medical care contributes 10 
to 20 percent of health and 
well-being,” said Bradley in 
a recent interview, “but you 
would think that medical care 
determined 100 percent of 
our health.” Th is outlook, she 
said, “is very much aligned 
with having created a very big 
medical complex that is quite 
profi table for many of us: It’s 
18 percent of our economy.”
Th e authors contend that 
doctors and patients alike 
seek medical care even for 
problems that could be solved 
through nonmedical means. 
In one case study, a physi-
cian pushes for surgery on a 
patient’s shoulder that heals 
successfully through physical 
therapy. In another, parents 
insist on one test after another 
to diagnose their teenager’s 
headaches, even after several 
doctors concur that the head-
aches arise from anxiety.
Th e United States has built 
its health care system on the 
assumption that people are 
largely responsible for their 
own welfare, said Bradley. 
As a counterpoint to American 
individualism, she and Taylor 
analyzed the attitudes of 
Scandinavians, who stay 
healthier while spending 
less. Th e authors found that 
Scandinavians are more 
open to collective action and 
far more willing to invest in 
projects beyond new hospi-
tal wings. “In Scandinavia,” 
Bradley said, “you could see 
left and right a broader under-
standing of the social deter-
minants of health”—factors 
like the quality of housing, 
the richness of social sup-
port, safe streets, and urban 
design that promotes exercise. 
Th e American viewpoint, on 
the other hand, essentially 
reduces health care to a trans-
action between two individu-
als: a doctor and a patient. “It 
would be hard for a popula-
tion with that basic culture 
[that is, American] to recog-
nize and invest in the parts of 
our health that are collectively 
determined,” said Bradley.
But she said that American 
physicians interviewed 
embraced the need for change. 
“Doctors we talked with said, 
‘I am in the emergency room 
with a patient who has diabe-
tes, and I can’t even get to dia-
betes and wound care because 
the person has so many social 
issues. I’m not even able to 
do my job.’ ” If the American 
system addressed health more 
comprehensively, Bradley 
argued, doctors could be freed 
to do medicine, the profes-
sion they trained for, without 
feeling the need to be social 
service providers as well.
   American society values access to 
 doctors and the latest medical technology over 
  social determinants of health.










































{Send notices of new books toYale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
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S I NC E 1949 Yale medical students have been lampooning their professors, deans, and class-
mates in an annual spoof that often revolves around goings-on at the School of Medicine. 
Th is year’s production, Th e Greatest Second-Year Show Ever?, presented by the Class of 2016, 
took as its theme the impending implementation of a new medical curriculum. Students were 
panicking over the show’s possible demise—the new curriculum left no time for such frivolity. 
(Any professor at the med school knows the folly of scheduling classes in the fi nal days before 
opening night.) As did past shows, this year’s installment targeted such familiar campus 
fi gures as Deputy Dean for Education Richard Belitsky, M.D.; Associate Dean for Student Affairs 
Nancy R. Angoff, M.P.H. ’81, M.D. ’90, HS ’93; Professor Margaret Bia, M.D.; and Professor 
Auguste Fortin, M.D., M.P.H. Jessica Ye and Simon Kigwana were the show’s producers.
—John Curtis
Th e greatest show ever?
Visit yalemedicine.yale.edu to see more pictures from this year's Second-Year Show.
end note
